Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer
Fast Track designation opens the potential for expedited development and review with the US FDAFast Track was granted based on...